Filetype
High-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are rare but have a very poor prognosis and represent a severely understudied class of tumours. Molecular data for HG GEP-NEN are limited and treatment strategies for the carcinoma subgroup (HG GEP-NEC) are extrapolated from small-cell lung cancer (SCLC). After pathological re-evaluation, we analysed DNA from tumours and m
Tumor dosimetry was performed for 177Lu-DOTA-TATE with the aims of better understanding i) the range and variation of the tumor absorbed doses (ADs), ii) how different dosimetric quantities evolve over the treatment cycles, and iii) whether this evolution differs depending on the tumor grade. Such information is important for radiobiological interpretation and may inform the design of alternative
BACKGROUND: Cardiac resynchronization therapy (CRT) restores ventricular synchrony and induces left ventricular (LV) reverse remodeling in patients with heart failure (HF) and dyssynchrony. However, 30% of treated patients are non-responders despite all efforts. Cardiac magnetic resonance imaging (CMR) can be used to quantify regional contributions to stroke volume (SV) as potential CRT predictors
Cerebral palsy (CP) comprises a heterogeneous group of conditions recognized by disturbances of movement and posture and is caused by a non-progressive injury to the developing brain. Birth prevalence of CP is about 2-2.5 per 1,000 live births. Although the motor impairment is the hallmark of the diagnosis, individuals with CP often have other impairments, including cognitive ones. Cognitive impai
BACKGROUND: Spasticity is present in more than 80% of the population with cerebral palsy (CP). The aim of this study was to describe and compare the use of three spasticity reducing methods; Botulinum toxin-A therapy (BTX-A), Selective dorsal rhizotomy (SDR) and Intrathecal baclofen therapy (ITB) among children and adolescents with CP in six northern European countries.METHODS: This registry-based
AIM: To describe the point prevalence of cerebral palsy (CP) and distribution of gross and fine motor function in individuals registered in a CP-North surveillance programme.METHOD: Aggregate data of individuals with CP aged 6 to 19 years, sex, CP subtype, and gross and fine motor function levels were collected from each programme. Overall and age-specific point prevalence of CP was calculated for
AIMS: This report reviews major laws, acts and regulations of social benefits and services for individuals with disabilities, focusing on cerebral palsy in the five Nordic countries. It summarizes the available benefits and services and the re-application process and provides comparative analyses among the countries.METHODS: Published reports, articles and relevant government and municipal website
BACKGROUND: Spina bifida (SB) is monitored through birth defects surveillance across the United States and in most developed countries. Although much is known about the management of SB and its many comorbid conditions in affected individuals, there are few systematic, longitudinal studies on population-based cohorts of children or adults. The natural history of SB across the life course of person
IMPORTANCE: There is a lack of agreement on what constitutes successful outcomes for the process of health care transition (HCT) among adolescent and young adults with special health care needs.OBJECTIVE: To present HCT outcomes identified by a Delphi process with an interdisciplinary group of participants.DESIGN, SETTING, AND PARTICIPANTS: A Delphi method involving 3 stages was deployed to refine
BackgroundIn Prostate-specific membrane antigen (PSMA) positron emission tomography with computed tomography (PET-CT), there is significant renal uptake. The standard in renal cortical functional imaging is scintigraphy with technetium-99m labeled dimercaptosuccinic acid (DMSA). Using [68Ga]Ga-PSMA-11 PET for renal imaging has been suggested, but using [18F]PSMA-1007 has not been explored. The aim
A polymer gel electrolyte comprising a metal salt, a polymer, optionally a plasticizer, characterized in that the polymer comprises a carbon-hydrogen base chain having at least two reactive groups incorporated wherein the reactive groups have different reactivities. The polymer gel electrolyte neutralises a passivating layer in the form of waste products produced in the electrolyte phase by the me
A binder and/or electrolyte material and method for production thereof, which material is intended to be used in the preparation of a porous electrode (5) for a cell (100), wherein the binder and/or electrolyte material (20) comprises an ion conducting polymer (10).
The present invention relates to a medical article for containing a pharmaceutical protein preparation comprising at least a first component and a second component, having at least one surface coated with a coating to reduce the friction between the two components and to reduce the protein adsorption to the coating. The coating is a hydrophilic coating whereby the hydrophilicity of the surface of
The present invention relates to a coating system, in particular to a coating system for articles where plastic materials slide against flexible rubber materials. The coating system is a silicone oil based coating having a viscosity of at least 200,000 centistokes, i.e. a high viscosity coating. The coating comprises in a preferred embodiment a silicone oil based block or graft copolymer, or segme
In an ampoule for a medicament the space accommodating the medicament is defined by an ampoule wall (1) a pierceable seal (5) closing one end of the ampoule and a piston (7) closing the other end of the ampoule. A metal containing fixation element (8) is secured to one of the parts defining the medicament accommodating space. A mixing element (9, 10) also containing a metal and having a density la
A medicament container for storing a liquid medicament, such as insulin, comprises a wall with at least two opposite portions made of a polymer material having a light transmission at 400 nm of at least 25%, a glass transition temperature above 50° C., and a density of 0.95 g/cm3 or more. The polymer material comprises at least 70% by weight of a copolymer material composed of aliphatic cyclic or
The present invention relates to a medicament container for storing a liquid medicament, such as insulin, the container comprising a distal and a proximal end portion and a wall, at least two opposite portions of the wall being of a polymer material. The thickness of the polymer wall portions is between 0.3 mm and 3 mm, and the light transmission through the polymer wall portions at 400 nm are at
